Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2018-99-116577

Published: 2018

Journal Articles

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

C. Escuriola Ettingshausen, Erik Berntorp, MD PhD, Yesim Dargaud, MD PhD, Zeynep Gutowski, PhD, Claude Negrier, Anna Pavlova, MD PhD, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 2482.

https://doi.org/10.1182/blood-2018-99-114408

Published: 2018

Journal Articles

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Ri Liesner, Joris Versteden, Shannely Lowndes, Larisa Belyanskaya, PhD, Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD

Blood (2018) 132 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2018-99-110608

Published: 2018

Journal Articles

Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII

Anna Pavlova, MD PhD, Irina Matytsina, Morio Arai, MD, Johannes Oldenburg, MD PhD

Blood (2014) 124 (21): 1527.

https://doi.org/10.1182/blood.V124.21.1527.1527

Published: 2014

Journal Articles

Deletion of Two Contiguous Genes, Platelet GPIbβ (Glycoprotein Ibβ) and Septin SEPT5, in a Boy with Bernard-Soulier Syndrome and Developmental Delay: A Possible New Contiguous Gene Syndrome.

Ingrid Bartsch, PhD, Ina Hainmann, MD, Susanne Bläser, PhD, Anna Pavlova, MD, Johannes Oldenburg, MD, Anja Busse, Francois Lanza, PhD, Paquita Nurden, MD, PhD, Andrea Superti-Furga, MD, Barbara Zieger, MD

Blood (2006) 108 (11): 1097.

https://doi.org/10.1182/blood.V108.11.1097.1097

Published: 2006

Journal Articles

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Heike Pfeifer, MD, Barbara Wassmann, MD, Anna Pavlova, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Dieter Hoelzer, MD, PhD, Oliver Ottmann, MD

Blood (2006) 108 (11): 639.

https://doi.org/10.1182/blood.V108.11.639.639

Published: 2006

NARROW

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII

Deletion of Two Contiguous Genes, Platelet GPIbβ (Glycoprotein Ibβ) and Septin SEPT5, in a Boy with Bernard-Soulier Syndrome and Developmental Delay: A Possible New Contiguous Gene Syndrome.

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Email alerts

ASH Publications

American Society of Hematology

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII

Deletion of Two Contiguous Genes, Platelet GPIbβ (Glycoprotein Ibβ) and Septin SEPT5, in a Boy with Bernard-Soulier Syndrome and Developmental Delay: A Possible New Contiguous Gene Syndrome.

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only